gert de schoenmakere · curriculum vitae sylvie rottey 1 sylvie rottey molenstraat 45 9890 gavere...
TRANSCRIPT
Curriculum Vitae Sylvie Rottey 1
Sylvie Rottey
Molenstraat 45
9890 Gavere
Belgium
Work : Ghent University Hospital
Drug Research Unit Ghent | Department of Medical Oncology
Entrance 52 – Route 5210 | Entrance 50 – Route 535
Corneel Heymanslaan 10
9000 Ghent
Belgium
Tel: +32 9 332 28 11 | Fax: +32 9 332 62 85
E-mail : [email protected]
Civil status : married, De Schoenmakere Gert,
Nephrologist, AZ Delta Roeselare-Menen-Torhout
Children: Britt (06/06/2001) and Dries (09/09/2003)
Nationality : Belgium
Date of birth : 29/07/1972
Place of birth : Gent, Belgium
TRAINING
1983 - 1990 : Latin-Sciences
Institute Maria Middelares -Aalter
Great distinction
09/07/1993 : Candidate in Medical Sciences
University of Gent, Belgium
1st year : distinction
2nd year : distinction
3rd year : distinction
01/07/1997 : Medical Doctor
University Gent, Belgium
1st year : distinction
2nd year : great distinction
3rd year : the greatest distinction
4th year : great distinction
1997 – 1998 : Trainee in internal medicine – 1st year
Heilig Hartziekenhuis – Roeselare
3 months : geriatrics
4 months : endocrinology
3 months : cardiology
2 months : medical oncology
Curriculum Vitae
Curriculum Vitae Sylvie Rottey 2
1998 – 1999 : Trainee in internal medicine – 2nd year
Heilig Hartziekenhuis - Roeselare
3 months : nephrology
3 months : gastro-enterology
5 months : pneumology
1 month : medical oncology
1999 – 2000 : Trainee in internal medicine – 3rd year (subdiscipline medical oncology)
University Hospital Gent
6 months : Medical Oncology – Prof. S. Van Belle
6 months : Hematology – Prof. W. Van Hove
2000 - 2001 : Trainee in internal medicine – 4th year (subdiscipline medical oncology)
University Hospital Gent
12 months : Medical Oncology – Prof. S. Van Belle
2001 - 2002 : Trainee in internal medicine – 5th year (subdiscipline medical oncology)
Université Descartes Paris V
Hôpital Pitié-Salpétrière, Paris
12 months : medical oncology – Prof. D. Khayat
Institut Gustave Roussy, Paris
12 months : basic research fellow – medical genetics – Dr. J. Benard
2002-2003 : Trainee in medical oncology
University Hospital Gent
Prof. S.Van Belle
October 2002 : Board Certificate of Internal Medicine
October 2003 : Application for the ‘Competence in Oncology in Internal Medicine’
October 2003 : Member of staff department Medical Oncology University Hospital Gent
30 March 2007 : PhD : Doctor in Medical Science 99mTc-HYNIC Annexin-V for monitoring response to chemotherapy:
methodology and feasibility studies.
Promotors : Prof. S. Van Belle and Prof. C. Van de Wiele
October 2008 : Associate Professor in Pharmacology
November 2008: Certificate of Clinical Pharmacology
October 2011 : Professor in Pharmacology
1 October 2015 : - Head of the Drug Research Unit Ghent (Phase I trials)
- Persisting staff member of the department of Medical Oncology (Head
and Neck cancers and Urogenital Cancers)
Currently working at the department of medical oncology as member of staff, responsible for
Head and Neck cancers and Urogenital Cancers.
Coordinator of the Oncology Phase I Unit of the hospital (from 2009 on).
Currently teaching different courses as professor in Pharmacology.
Curriculum Vitae Sylvie Rottey 3
PRIZES
1997 : Prize for the best oral presentation during the BVN meeting
(Belgian Society of Nephrology), Brussels, Belgium
1997 : Scientific symposium of the Belgian Society for Internal
medicine, oral presentation : “Progression of renal failure in
patients with compromised renal function is not always
present: evaluation of underlying disease.”
Prize for the best oral presentation
1998 : VENEB, Belgium : Multipele adenopathies in an enlarged
small bowel meso in disseminated Giardia Lamblia
parasitosis.
Prize for the best oral presentation
2003 : Organotypic culture of primary breast cancer tissue :
feasibility of the multicellular spheroid model.
Prize for oral presentation – BSMO
Curriculum Vitae Sylvie Rottey 4
PUBLICATIONS
Publications in international journals
1. Rottey S, Vanholder R, De Schoenmakere G, Lameire N. Progression of
renal failure in patients with compromised renal function is not always
present: evaluation of underlying disease. Clin Nephrol. 2000;54(1):1-10.
2. De Schoenmakere G, Vanholder R, Rottey S, Duym P, Lameire N.
Relationship between gastric emptying and clinical and biochemical
factors in chronic haemodialysis patients. Nephrol Dial Transplant.
2001;16(9):1850-5.
3. Van de Wiele C, Rottey S, Goethals I, Buscombe J, Van Belle S, De Vos F,
Dierckx RA. 99mTc sestamibi and 99mTc tetrofosmin scintigraphy for
predicting resistance to chemotherapy: a critical review of clinical data.
Nucl Med Commun. 2003;24(9):945-50.
4. Vermeersch H, Ham H, Rottey S, Lahorte C, Corsetti F, Dierckx R, Steinmetz
N, Van de Wiele C. Intraobserver, interobserver, and day-to-day
reproducibility of quantitative 99mTc-HYNIC annexin-V imaging in head
and neck carcinoma. Cancer Biother Radiopharm. 2004;19(2):205-10.
5. De Schoenmakere G, De Waele J, Terryn W, Deweweire M, Verstraete A,
Hoste E, Rottey S, Lameire N, Colardyn F. Phenytoin intoxication in critically
ill patients. Am J Kidney Dis. 2005;45(1):189-92.
6. Hennin C, Diederichsen E, Rottey L, Höfte M. Engineering disease
resistance in plants using the CF9-AVR9 two component system. Meded
Rijksuniv Gent Fak Landbouwkd Toegep Biol Wet. 2001;66(4):29-34.
7. Méric JB, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O, Spano JP.
Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev
Oncol Hematol. 2006;59(1):51-64.
8. Rottey S, Slegers G, Van Belle S, Goethals I, Van de Wiele C. Sequential
99mTc-hydrazinonicotinamide-annexin V imaging for predicting response
to chemotherapy. J Nucl Med. 2006;47(11):1813-8.
9. Hoebeke PB, Rottey S, Van Heddeghem N, Villeirs G, Pauwels P,
Schrauwen W, Ceulemans P, Monstrey S. One-stage penectomy and
phalloplasty for epithelioid sarcoma of the penis in an adolescent. Eur Urol.
2007;51(5):1429-32.
10. Rottey S, Loose D, Vakaet L, Lahorte C, Vermeersch H, Van Belle S, Van de
Wiele C. 99mTc-HYNIC Annexin-V imaging of tumors and its relationship to
response to radiotherapy and/or chemotherapy. Q J Nucl Med Mol
Imaging. 2007;51(2):182-8.
Curriculum Vitae Sylvie Rottey 5
11. Rottey S, Petrovic M, Bauters W, Mervillie K, Vanherreweghe E, Bonte K,
Van Belle S, Vermeersch H. Evaluation of metastatic lymph nodes in head
and neck cancer: a comparative study between palpation,
ultrasonography, ultrasound-guided fine needle aspiration cytology and
computed tomography. Acta Clin Belg. 2006;61(5):236-41.
12. Rottey S, Signore A, Van de Wiele C. Radiolabelled chemotherapeutics.
Q J Nucl Med Mol Imaging. 2007;51(2):139-51.
13. Hoebeke PB, Rottey S, Van Heddeghem N, Villeirs G, Pauwels P,
Schrauwen W, Ceulemans P, Monstrey S. One-stage penectomy and
phalloplasty for epithelioid sarcoma of the penis in an adolescent: part 2.
Eur Urol. 2007;51(6):1744-7.
14. Bambust I, Van Aelst F, Joosens E, Schallier D, Rezaei Kalantari H, Paulus Rs,
Renard V, Clausse M, Duck L, Luce S, Pierre P, Van Belle S, Rottey S. A
Belgian registry of interleukin-2 administration for treatment of metastatic
renal cell cancer and confrontation with literature data. Acta Clin Belg.
2007;62(4):223-9.
15. Ost P, Rottey S, Smeets P, Boterberg T, Stragier B, Goethals I. F-18
fluorodeoxyglucose PET/CT scanning in the diagnostic work-up of a
primary pericardial mesothelioma: a case report. J Thorac Imaging.
2008;23(1):35-8.
16. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J,
Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko
I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. Platinum-
based chemotherapy plus cetuximab in head and neck cancer. N Engl J
Med. 2008;359(11):1116-27.
17. Rottey S, Van den Bossche B, Slegers G, Van Belle S, van de Wiele C.
Influence of chemotherapy on the biodistribution of
[99mTc]hydrazinonicotinamide annexin V in cancer patients. Q J Nucl
Med Mol Imaging. 2009;53(2):127-32.
18. Verbeke N, Verstraete K, Sys G, Forsyth R, Kluyskens D, Denys H,
Uyttendaele D, Rottey S. Osteosarcoma with extensive calcified pleural
metastases at diagnosis. Acta Clin Belg. 2008;63(5):325-8.
19. van Fraeyenhove F, Lamot C, Vogelaers D, Van Belle S, Cesmeli E, Rottey
S. A rare infectious complication after endoscopic ultrasound guided fine
needle aspiration in an oncological patient and review of the literature.
Acta Clin Belg. 2009;64(2):147-9.
20. Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, Epstein
RJ, Baker KL, McCann L, Crofts T, Pandite L, Figlin RA. Efficacy and safety
Curriculum Vitae Sylvie Rottey 6
of pazopanib in patients with metastatic renal cell carcinoma. J Clin
Oncol. 2010;28(3):475-80.
21. Mesía R, Rivera F, Kawecki A, Rottey S, Hitt R, Kienzer H, Cupissol D, De
Raucourt D, Benasso M, Koralewski P, Delord JP, Bokemeyer C, Curran D,
Gross A, Vermorken JB. Quality of life of patients receiving platinum-based
chemotherapy plus cetuximab first line for recurrent and/or metastatic
squamous cell carcinoma of the head and neck. Ann Oncol.
2010;21(10):1967-73.
22. Verbaeys C, Hoebeke P, Van Belle S, Rottey S. Targeted therapy for
metastatic renal cell cancer. Acta Clin Belg. 2010;65(2):115-21.
23. Licitra L, Mesia R, Rivera F, Remenár E, Hitt R, Erfán J, Rottey S, Kawecki A,
Zabolotnyy D, Benasso M, Störkel S, Senger S, Stroh C, Vermorken JB.
Evaluation of EGFR gene copy number as a predictive biomarker for the
efficacy of cetuximab in combination with chemotherapy in the first-line
treatment of recurrent and/or metastatic squamous cell carcinoma of the
head and neck: EXTREME study. Ann Oncol. 2011;22(5):1078-87.
24. De Maeseneer DJ, Lambert B, Surmont V, Geboes K, Rottey SW. 18-
Fluorodeoxyglucose positron emission tomography as a tool for response
prediction in solid tumours. Acta Clin Belg. 2010;65(5):291-9.
25. Lamot C, Rottey S, De Backer T, Van Bortel L, Robays H, Van Belle S, Denys
H, Cocquyt V. Cardiac toxicity of trastuzumab: experience at the Ghent
Unversity Hospital, Belgium. Acta Clin Belg. 2010;65(5):300-4.
26. Rottey S, Madani I, Deron P, Van Belle S. Modern treatment for
nasopharyngeal carcinoma: current status and prospects. Curr Opin
Oncol. 2011;23(3):254-8.
27. Kruse V, Rottey S, De Backer O, Van Belle S, Cocquyt V, Denys H. PARP
inhibitors in oncology: a new synthetic lethal approach to cancer therapy.
Acta Clin Belg. 2011;66(1):2-9.
28. Deron P, Mertens K, Goethals I, Rottey S, Duprez F, De Neve W, Vermeersch
H, Van de Wiele C. Metabolic tumour volume. Prognostic value in locally
advanced squamous cell carcinoma of the head and neck.
Nuklearmedizin. 2011;50(4):141-6.
29. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones
RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig
TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg
CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D,
Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators.
Abiraterone and increased survival in metastatic prostate cancer. N Engl
J Med. 2011;364(21):1995-2005.
Curriculum Vitae Sylvie Rottey 7
30. Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin
J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O,
Rosamilia M, Booth J, Pirotta N, Bodrogi I; REACT Study Group. An
international expanded-access programme of everolimus: addressing
safety and efficacy in patients with metastatic renal cell carcinoma who
progress after initial vascular endothelial growth factor receptor-tyrosine
kinase inhibitor therapy. Eur J Cancer. 2012;48(3):324-32.
31. Kruse V, Noens L, Lumen N, Hoebeke P, Van Belle S, Rottey S. High dose
chemotherapy and stem cell rescue for metastatic germ cell tumours:
long-term results from a single institution. Acta Clin Belg. 2011;66(4):254-9.
32. Combes M, Rottey S, De Backer T. Cardiovascular toxicity of cancer
treatment. Acta Clin Belg. 2011;66(4):260-6.
33. Lameire N, Kruse V, Rottey S. Nephrotoxicity of anticancer drugs--an
underestimated problem? Acta Clin Belg. 2011;66(5):337-45.
34. Seront E, Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeve V, Canon
JL, Dopchie C, Vandenbulcke JM, Whenham N, Goeminne JC, Clausse M,
Verhoeven D, Glorieux P, Branders S, Dupont P, Schoonjans J, Feron O,
Machiels JP. Phase II study of everolimus in patients with locally advanced
or metastatic transitional cell carcinoma of the urothelial tract: clinical
activity, molecular response, and biomarkers. Ann Oncol.
2012;23(10):2663-70.
35. Vermassen T, Speeckaert MM, Lumen N, Rottey S, Delanghe JR.
Glycosylation of prostate specific antigen and its potential diagnostic
applications. Clin Chim Acta. 2012;413(19-20):1500-5.
36. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN,
North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr,
Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS; COU-AA-301
Investigators. Abiraterone acetate for treatment of metastatic castration-
resistant prostate cancer: final overall survival analysis of the COU-AA-301
randomised, double-blind, placebo-controlled phase 3 study. Lancet
Oncol. 2012;13(10):983-92.
37. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi
K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ,
Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen
WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano
CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302
Investigators. Abiraterone in metastatic prostate cancer without previous
chemotherapy. N Engl J Med. 2013;368(2):138-48.
Curriculum Vitae Sylvie Rottey 8
38. Vermorken JB, Rottey S, Ehrnrooth E, Pelling K, Lahogue A, Wind S, Machiels
JP. A phase Ib, open-label study to assess the safety of continuous oral
treatment with afatinib in combination with two chemotherapy regimens:
cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with
advanced solid tumors. Ann Oncol. 2013;24(5):1392-400.
39. Maison-Blanche P, Vermorken JB, Goksel T, Machiels JP, Agarwala S,
Rottey S, Daugaard G, Volovat C, Scheulen M, Sengeløv L, Grecea D, Eniu
A, Jäger E, Meiri E, Cascinu S, Strumberg D, Demir G, Clemens M, Pinotti G,
Nardi M, Guthrie T, Boelle E, Magherini E. A randomized, double-blind,
placebo-controlled study to assess QTc interval prolongation of standard
dose aflibercept in cancer patients treated with docetaxel. J Cardiovasc
Pharmacol. 2013;61(6):495-504.
40. Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E,
Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, Pai VR, Faivre S,
Blajman CR, Forastiere AA, Stein BN, Oliner KS, Pan Z, Bach BA; SPECTRUM
investigators. Cisplatin and fluorouracil with or without panitumumab in
patients with recurrent or metastatic squamous-cell carcinoma of the
head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Lancet Oncol. 2013;14(8):697-710.
41. Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella
D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI; COU-
AA-301 Investigators. Effect of abiraterone acetate treatment on the
quality of life of patients with metastatic castration-resistant prostate
cancer after failure of docetaxel chemotherapy. Eur J Cancer.
2013;49(17):3648-57.
42. Vermassen T, Van Praet C, Vanderschaeghe D, Maenhout T, Lumen N,
Callewaert N, Hoebeke P, Van Belle S, Rottey S, Delanghe J. Capillary
electrophoresis of urinary prostate glycoproteins assists in the diagnosis of
prostate cancer. Electrophoresis. 2014;35(7):1017-24.
43. Van Praet C, Libbrecht L, D'Hondt F, Decaestecker K, Fonteyne V,
Verschuere S, Rottey S, Praet M, De Visschere P, Lumen N; Uro-Oncology
Group Ghent. Agreement of Gleason score on prostate biopsy and
radical prostatectomy specimen: is there improvement with increased
number of biopsy cylinders and the 2005 revised Gleason scoring? Clin
Genitourin Cancer. 2014;12(3):160-6.
44. Kruse V, Somers A, Van Bortel L, De Both A, Van Belle S, Rottey S. Sunitinib
for metastatic renal cell cancer patients: observational study highlighting
the risk of important drug-drug interactions. J Clin Pharm Ther.
2014;39(3):259-65.
Curriculum Vitae Sylvie Rottey 9
45. Pottel L, Lycke M, Boterberg T, Pottel H, Goethals L, Duprez F, Van Den
Noortgate N, De Neve W, Rottey S, Geldhof K, Buyse V, Kargar-Samani K,
Ghekiere V, Debruyne PR. Serial comprehensive geriatric assessment in
elderly head and neck cancer patients undergoing curative radiotherapy
identifies evolution of multidimensional health problems and is indicative
of quality of life. Eur J Cancer Care (Engl). 2014;23(3):401-12.
46. Maison-Blanche P, Dakhil S, Baron A, Rottey S, Millard F, Daugaard G,
Machiels JP, Conkright W, Sharma S, Soetekouw PM, Yachnin J, Sengeløv
L, Van Veldhuizen P, Agarwala SS, Sémiond D, Chadjaa M, Shen L, Wade
JL. An open-label study to investigate the cardiac safety profile of
cabazitaxel in patients with advanced solid tumors. Cancer Chemother
Pharmacol. 2014;73(6):1241-52.
47. Ruzsa A, Sen M, Evans M, Lee LW, Hideghety K, Rottey S, Klimak P,
Holeckova P, Fayette J, Csoszi T, Erfan J, Forssmann U, Goddemeier T,
Bexon A, Nutting C; NA EMD 1201081 Study Group. Phase 2, open-label,
1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in
combination with cetuximab in second-line cetuximab-naïve patients
with recurrent or metastatic squamous cell carcinoma of the head and
neck (R/M SCCHN). Invest New Drugs. 2014;32(6):1278-84.
48. Van Praet C, Decaestecker K, Fonteyne V, Ost P, De Visschere P,
Verschuere S, Rottey S, Lumen N. Contemporary minimally-invasive
extended pelvic lymph node dissection for prostate cancer before
curative radiotherapy: prospective standardized analysis of
complications. Int J Urol. 2014;21(11):1138-43.
49. Cornelis N, Vermassen T, Schallier D, Machiels JP, Gil T, Debruyne PR,
D'hondt R, Bols A, Schrijvers D, Mebis J, Lumen N, Rottey S. Prospective non-
interventional multicentre observational trial of first-line anti-cancer
treatment in patients with metastatic renal cell cancer in Belgium. Acta
Clin Belg. 2014;69(5):335-40.
50. Naert E, De Bleecker JL, Lumen N, Rottey S. Necrotizing myopathy as a
paraneoplastic syndrome associated with renal cell carcinoma. Acta Clin
Belg. 2015;70(1):61-4.
51. Pottel L, Lycke M, Boterberg T, Pottel H, Goethals L, Duprez F, Maes A,
Goemaere S, Rottey S, Foubert I, Debruyne PR. Echium oil is not protective
against weight loss in head and neck cancer patients undergoing
curative radio(chemo)therapy: a randomised-controlled trial. BMC
Complement Altern Med. 2014;14:382.
52. Vermassen T, Van Praet C, Lumen N, Decaestecker K, Vanderschaeghe
D, Callewaert N, Villeirs G, Hoebeke P, Van Belle S, Rottey S, Delanghe J.
Curriculum Vitae Sylvie Rottey 10
Urinary prostate protein glycosylation profiling as a diagnostic biomarker
for prostate cancer. Prostate. 2015 Feb 15;75(3):314-22.
53. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K,
Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS,
de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh
T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators. Abiraterone
acetate plus prednisone versus placebo plus prednisone in
chemotherapy-naive men with metastatic castration-resistant prostate
cancer (COU-AA-302): final overall survival analysis of a randomised,
double-blind, placebo-controlled phase 3 study. Lancet Oncol.
2015;16(2):152-60.
54. De Maeseneer DJ, Van Praet C, Lumen N, Rottey S. Battling resistance
mechanisms in antihormonal prostate cancer treatment: Novel agents
and combinations. Urol Oncol. 2015 Jul;33(7):310-21.
55. Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB,
Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de
Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ,
Ehrnrooth E, Cohen EE; LUX-H&N 1 investigators. Afatinib versus
methotrexate as second-line treatment in patients with recurrent or
metastatic squamous-cell carcinoma of the head and neck progressing
on or after platinum-based therapy (LUX-Head & Neck 1): an open-label,
randomised phase 3 trial. Lancet Oncol. 2015;16(5):583-94.
56. Jacobs J, Deschoolmeester V, Zwaenepoel K, Rolfo C, Silence K, Rottey S,
Lardon F, Smits E, Pauwels P. CD70: An emerging target in cancer
immunotherapy. Pharmacol Ther. 2015;155:1-10.
57. Machiels JP, Peeters M, Herremans C, Surmont V, Specenier P, De Smet M,
Pilz K, Strelkowa N, Liu D, Rottey S. A phase I study of volasertib combined
with afatinib, in advanced solid tumors. Cancer Chemother Pharmacol.
2015;76(4):843-51.
58. Bracarda S, Rottey S, Bahl A, Eichelberg C, Mellado B, Mangel L, Cattaneo
A, Panneerselvam A, Grünwald V. REACT expanded-access program in
patients with metastatic renal cell carcinoma: real-world data from a
European subanalysis. Future Oncol. 2015;11(21):2893-903.
59. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S,
Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK,
Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y,
Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA,
Waxman IM, Sharma P; CheckMate 025 Investigators. Nivolumab versus
Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med.
2015;373(19):1803-13.
Curriculum Vitae Sylvie Rottey 11
60. Vermassen T, Van Praet C, Poelaert F, Lumen N, Decaestecker K, Hoebeke
P, Van Belle S, Rottey S, Delanghe J. Diagnostic accuracy of urinary
prostate protein glycosylation profiling in prostatitis diagnosis. Biochem
Med (Zagreb). 2015;25(3):439-49.
61. Pottel L, Lycke M, Boterberg T, Pottel H, Goethals L, Duprez F, Rottey S,
Lievens Y, Van Den Noortgate N, Geldhof K, Buyse V, Kargar-Samani K,
Ghekiere V, Debruyne PR. G-8 indicates overall and quality-adjusted
survival in older head and neck cancer patients treated with curative
radiochemotherapy. BMC Cancer. 2015;15:875.
62. Decoster L, Vande Broek I, Neyns B, Majois F, Baurain JF, Rottey S, Rorive A,
Anckaert E, De Mey J, De Brakeleer S, De Grève J. Biomarker Analysis in a
Phase II Study of Sunitinib in Patients with Advanced Melanoma.
Anticancer Res. 2015;35(12):6893-9.
63. Seront E, Rottey S, Filleul B, Glorieux P, Goeminne JC, Verschaeve V,
Vandenbulcke JM, Sautois B, Boegner P, Gillain A, van Maanen A,
Machiels JP. Phase II study of dual phosphoinositol-3-kinase (PI3K) and
mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with
locally advanced or metastatic transitional cell carcinoma. BJU Int.
2016;118(3):408-15.
64. Van Praet C, Rottey S, Van Hende F, Pelgrims G, Demey W, Van Aelst F,
Wynendaele W, Gil T, Schatteman P, Filleul B, Schallier D, Machiels JP,
Schrijvers D, Everaert E, D'Hondt L, Werbrouck P, Vermeij J, Mebis J, Clausse
M, Rasschaert M, Van Erps J, Verheezen J, Van Haverbeke J, Goeminne
JC, Lumen N. Abiraterone acetate post-docetaxel for metastatic
castration-resistant prostate cancer in the Belgian compassionate use
program. Urol Oncol. 2016;34(6):254.e7-254.e13.
65. Vermassen T, De Meulenaere A, Van de Walle M, Rottey S. Therapeutic
approaches in clear cell and non-clear cell renal cell carcinoma. Acta
Clin Belg. 2017 Feb;72(1):12-18.
66. De Meulenaere A, Vermassen T, Aspeslagh S, Zwaenepoel K, Deron P,
Duprez F, Ferdinande L, Rottey S. CD70 Expression and Its Correlation with
Clinicopathological Variables in Squamous Cell Carcinoma of the Head
and Neck. Pathobiology. 2016;83(6):327-33.
67. Van de Walle M, Demol J, Staelens L, Rottey S. Abscopal effect in
metastatic renal cell carcinoma. Acta Clin Belg. 2017;72(4):245-249.
68. De Scheerder MA, Rottey S, Mariman A, Praet M, Vogelaers D. How far to
investigate presumed psychosomatic symptoms: Lessons from a particular
case…. Acta Clin Belg. 2017;72(2):138-141.
Curriculum Vitae Sylvie Rottey 12
69. Dirix L, Swaisland H, Verheul HM, Rottey S, Leunen K, Jerusalem G, Rolfo C,
Nielsen D, Molife LR, Kristeleit R, Vos-Geelen J, Mau-Sørensen M,
Soetekouw P, van Herpen C, Fielding A, So K, Bannister W, Plummer R.
Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib
in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label
Studies. Clin Ther. 2016;38(10):2286-2299.
70. Azaro A, Rodón J, Machiels JP, Rottey S, Damian S, Baird R, Garcia-
Corbacho J, Mathijssen RHJ, Clot PF, Wack C, Shen L, de Jonge MJA. A
phase I pharmacokinetic and safety study of cabazitaxel in adult cancer
patients with normal and impaired renal function. Cancer Chemother
Pharmacol. 2016;78(6):1185-1197.
71. Machiels JP, Van Maanen A, Vandenbulcke JM, Filleul B, Seront E, Henry
S, D'Hondt L, Lonchay C, Holbrechts S, Boegner P, Brohee D, Dequanter D,
Louviaux I, Sautois B, Whenham N, Berchem G, Vanderschueren B,
Fontaine C, Schmitz S, Gillain A, Schoonjans J, Rottey S. Randomized Phase
II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent
and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Previously Treated With Platinum-Based Therapy. Oncologist.
2016;21(12):1416-e17.
72. De Meulenaere A, Vermassen T, Aspeslagh S, Vandecasteele K, Rottey S,
Ferdinande L. TILs in Head and Neck Cancer: Ready for Clinical
Implementation and Why (Not)? Head Neck Pathol. 2017;11(3):354-363.
73. Poelaert F, Kumps C, Lumen N, Verschuere S, Libbrecht L, Praet M, Rottey
S, Claeys T, Ost P, Decaestecker K, De Meerleer G, Van Praet C. Androgen
Receptor Gene Copy Number and Protein Expression in Treatment-Naïve
Prostate Cancer. Urol Int. 2017;99(2):222-228.
74. De Maeseneer DJ, Delafontaine B, Rottey S. Checkpoint inhibition: new
treatment options in urologic cancer. Acta Clin Belg. 2017;72(1):24-28.
75. Claeys T, Lumen N, Kumps C, Praet M, De Meerleer G, Rottey S, Ost P,
Devisschere P, Villeirs G, Fonteyne V, Decaestecker K. The independent
oncological role for cytoreductive nephrectomy in metastatic renal cell
carcinoma: Prognostic features in the era of targeted therapies. Urol
Oncol. 2017;35(4):152.e13-152.e22.
76. Van Praet C, Rottey S, Van Hende F, Pelgrims G, Demey W, Van Aelst F,
Wynendaele W, Gil T, Schatteman P, Filleul B, Schallier D, Machiels JP,
Schrijvers D, Everaert E, D'Hondt L, Werbrouck P, Vermeij J, Mebis J, Clausse
M, Rasschaert M, Van Erps J, Verheezen J, Van Haverbeke J, Goeminne
JC, Lumen N. Which Factors Predict Overall Survival in Patients With
Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone
Acetate Post-Docetaxel? Clin Genitourin Cancer. 2017;15(4):502-508.
Curriculum Vitae Sylvie Rottey 13
77. Vermassen T, D'Herde K, Jacobus D, Van Praet C, Poelaert F, Lumen N,
Callewaert N, Decaestecker K, Villeirs G, Hoebeke P, Van Belle S, Rottey S,
Delanghe J. Release of urinary extracellular vesicles in prostate cancer is
associated with altered urinary N-glycosylation profile. J Clin Pathol.
2017;70(10):838-846.
78. Zwaenepoel K, Jacobs J, De Meulenaere A, Silence K, Smits E, Siozopoulou
V, Hauben E, Rolfo C, Rottey S, Pauwels P. CD70 and PD-L1 in anaplastic
thyroid cancer - promising targets for immunotherapy. Histopathology.
2017;71(3):357-365.
79. De Meulenaere A, Vermassen T, Aspeslagh S, Zwaenepoel K, Deron P,
Duprez F, Rottey S, Ferdinande L. Prognostic markers in oropharyngeal
squamous cell carcinoma: focus on CD70 and tumour infiltrating
lymphocytes. Pathology. 2017;49(4):397-404.
80. Vermassen T, Geboes K, De Man M, Laurent S, Decoene E, Lumen N,
Delanghe J, Rottey S. Neither creatinine- nor cystatin C-estimated
glomerular filtration rate is optimal in oncology patients treated with
targeted agents. Nephrol Dial Transplant. 2018;33(3):402-408.
81. De Meulenaere A, Vermassen T, Aspeslagh S, Huvenne W, Van Dorpe J,
Ferdinande L, Rottey S. Turning the tide: Clinical utility of PD-L1 expression
in squamous cell carcinoma of the head and neck. Oral Oncol.
2017;70:34-42.
82. Duprez F, Berwouts D, De Neve W, Bonte K, Boterberg T, Deron P, Huvenne
W, Rottey S, Mareel M. Distant metastases in head and neck cancer. Head
Neck. 2017;39(9):1733-1743.
83. Sundahl N, De Wolf K, Rottey S, Decaestecker K, De Maeseneer D,
Meireson A, Goetghebeur E, Fonteyne V, Verbeke S, De Visschere P,
Reynders D, Van Gele M, Brochez L, Ost P. A phase I/II trial of fixed-dose
stereotactic body radiotherapy with sequential or concurrent
pembrolizumab in metastatic urothelial carcinoma: evaluation of safety
and clinical and immunologic response. J Transl Med. 2017;15(1):150.
84. Aftimos P, Rolfo C, Rottey S, Offner F, Bron D, Maerevoet M, Soria JC, Moshir
M, Dreier T, Van Rompaey L, Michot JM, Silence K, Hultberg A, Gandini D,
de Haard H, Ribrag V, Peeters M, Thibault A, Leupin N, Awada A. Phase I
Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced
Malignancies. Clin Cancer Res. 2017;23(21):6411-6420.
85. De Wolf K, Rottey S, Vermaelen K, Decaestecker K, Sundahl N, De Lobel L,
Goetghebeur E, De Meerleer G, Lumen N, Fonteyne V, De Maeseneer D,
Ost P. Combined high dose radiation and pazopanib in metastatic renal
Curriculum Vitae Sylvie Rottey 14
cell carcinoma: a phase I dose escalation trial. Radiat Oncol.
2017;12(1):157.
86. Jacobs J, Deschoolmeester V, Rolfo C, Zwaenepoel K, Van den Bossche
J, Deben C, Silence K, de Haard H, Hermans C, Rottey S, Vangestel C,
Lardon F, Smits E, Pauwels P. Preclinical data on the combination of
cisplatin and anti-CD70 therapy in non-small cell lung cancer as an
excellent match in the era of combination therapy. Oncotarget.
2017;8(43):74058-74067.
87. De Meulenaere A, Vermassen T, Aspeslagh S, Deron P, Duprez F, Laukens
D, Van Dorpe J, Ferdinande L, Rottey S. Tumor PD-L1 status and CD8+
tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal
cancer. Oncotarget. 2017;8(46):80443-80452.
88. Cammaert T, Decaestecker K, Sundahl N, Rottey S, Devreese KMJ. A
patient with acquired factor X deficiency and metastatic transitional cell
carcinoma of the bladder: is there a link between metastasis and factor
deficiency in solid tumors? Ann Hematol. 2018;97(3):545-546.
89. Sundahl N, Rottey S, De Maeseneer D, Ost P. Pembrolizumab for the
treatment of bladder cancer. Expert Rev Anticancer Ther. 2018;18(2):107-
114.
90. Buelens S, Poelaert F, Dhondt B, Fonteyne V, De Visschere P, Ost P, Verbeke
S, Villeirs G, De Man K, Rottey S, Decaestecker K, Lumen N. Metastatic
burden in newly diagnosed hormone-naive metastatic prostate cancer:
Comparing definitions of CHAARTED and LATITUDE trial. Urol Oncol.
2018;36(4):158.e13-158.e20.
91. Schatteman J, Van Gestel D, Berwouts D, De Gersem W, De Kerf G, De
Neve W, De Ost B, Olteanu AML, Rottey S, Vercauteren T, Goethals I,
Duprez F. A feasibility study on adaptive 18F-FDG-PET-guided radiotherapy
for recurrent and second primary head and neck cancer in the previously
irradiated territory. Strahlenther Onkol. 2018;194(8):727-736.
92. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri
TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F,
Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud
A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen
AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers
HJ, Escudier B; CheckMate 214 Investigators. Nivolumab plus Ipilimumab
versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med.
2018;378(14):1277-1290.
93. Lonez C, Hendlisz A, Shaza L, Aftimos P, Vouche M, Donckier V, Machiels
JH, Van Den Eynde M, Canon JL, Carrasco J, Odunsi K, Sahebjam S, Rottey
Curriculum Vitae Sylvie Rottey 15
S, Braun N, Verma B, Gilham DE, Lehmann FF. Celyad's novel CAR T-cell
therapy for solid malignancies. Curr Res Transl Med. 2018;66(2):53-56.
94. De Meulenaere A, Vermassen T, Creytens D, Aspeslagh S, Deron P, Duprez
F, Rottey S, Van Dorpe JA, Ferdinande L. Importance of choice of materials
and methods in PD-L1 and TIL assessment in oropharyngeal squamous cell
carcinoma. Histopathology. 2018;73(3):500-509.
95. Buelens S, De Bleser E, Dhondt B, Verla W, Decaestecker K, Ost P, Fonteyne
V, De Man K, Standaert C, Rottey S, Lumen N. Importance of metastatic
volume in prognostic models to predict survival in newly diagnosed
metastatic prostate cancer. World J Urol. 2018. [Epub ahead of print]
96. Fonteyne V, Rammant E, Ost P, Lievens Y, De Troyer B, Rottey S, De
Meerleer G, De Maeseneer D, De Ridder D, Decaestecker K. Evaluating
the Current Place of Radiotherapy as Treatment Option for Patients With
Muscle Invasive Bladder Cancer in Belgium. Clin Genitourin Cancer.
2018;16(6):e1159-e1169.
97. Plummer R, Verheul HM, De Vos FYFL, Leunen K, Molife LR, Rolfo C,
Grundtvig-Sørensen P, De Grève J, Rottey S, Jerusalem G, Italiano A, Spicer
J, Dirix L, Goessl C, Birkett J, Spencer S, Learoyd M, Bailey C, Dean E.
Pharmacokinetic Effects and Safety of Olaparib Administered with
Endocrine Therapy: A Phase I Study in Patients with Advanced Solid
Tumours. Adv Ther. 2018;35(11):1945-1964.
98. Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, van
Velthoven R, Del Pilar Laguna M, Wood L, van Melick HHE, Aarts MJ, Lattouf
JB, Powles T, de Jong IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette
L, Haanen J. Comparison of Immediate vs Deferred Cytoreductive
Nephrectomy in Patients with Synchronous Metastatic Renal Cell
Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.
JAMA Oncol. 2018. [Epub ahead of print]
99. Sundahl N, Vandekerkhove G, Decaestecker K, Meireson A, De Visschere
P, Fonteyne V, De Maeseneer D, Reynders D, Goetghebeur E, Van Dorpe
J, Verbeke S, Annala M, Brochez L, Van der Eecken K, Wyatt AW, Rottey S,
Ost P. Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus
Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial
Carcinoma. Eur Urol. 2019. [Epub ahead of print]
100. Machiels JP, Salazar R, Rottey S, Duran I, Dirix L, Geboes K, Wilkinson-Blanc
C, Pover G, Alvis S, Champion B, Fisher K, McElwaine-Johnn H, Beadle J,
Calvo E. A phase 1 dose escalation study of the oncolytic adenovirus
enadenotucirev, administered intravenously to patients with epithelial
solid tumors (EVOLVE). J Immunother Cancer. 2019;7(1):20.
Curriculum Vitae Sylvie Rottey 16
101. Vermassen T, De Bruyne S, Himpe J, Lumen N, Callewaert N, Rottey S,
Delanghe J. N-Linked Glycosylation and Near-Infrared Spectroscopy in
the Diagnosis of Prostate Cancer. Int J Mol Sci. 2019;20(7).
102. Seront E, Schmitz S, Papier M, van Maanen A, Henry S, Lonchay C, Rottey
S, van Caloen G, Machiels JP. Phase 1 Study Evaluating the Association of
the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in
Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the
Head and Neck. Front Oncol. 2019;9:155.
Publications in national journals
1. Rottey S. Doelgerichte kankertherapieën. Tijdschrift Voor Geneeskunde.
2008;64(21):1087-1090.
2. De Corte W, Rottey S, Depuydt P, Nollet J, Phillipé J, Benoit D. Trombotische
microangiopathie als eerste teken van gemetastaseerd borstcarcinoom.
Tijdschrift Voor Geneeskunde. 2009;65(1):34-37.
3. Rottey S, Van Bortel L, Van Belle S. Complicaties van oncologische
therapie thuis opvangen. Tijdschrift Voor Geneeskunde. 2009;65(4):116-
119.
4. Lapeire L, Debruyne J, Rottey S. Mitoxantrone chemotherapie voor de
behandeling van Multiple Sclerose. Tijdschrift Voor Geneeskunde.
2009;65(20):967-970.
5. Geboes K, Rottey S, Laurent S, Vandenbroucke J, Peeters M. Doe-het-zelf
Chemotherapieadvies’: gevaarlijke ontwikkelingen via het internet.
Tijdschrift Voor Geneeskunde. 2011; 67(6):261-266.
6. Kruse V, Lumen N, D’Hondt F, Rottey S. An update on the systemic
treatment of renal cell cancer. Belg J Med Oncol 2012;6(1):13-22.
7. Decaestecker K, De Meerleer G, Rottey S, Lumen N, Fonteyne V,
Oosterlinck W. Blaasconserverende behandelingen voor invasieve
blaaskanker: een te weinig gebruikte mogelijkheid. Tijdschrift Voor
Geneeskunde 2012;68(6):290-294.
8. Lapeire L, Deron P, Duprez F, Rottey S. De plaats van cetuximab in de
behandeling van hoofd- en halstumoren. Tijdschrift Voor Geneeskunde
2012;68(17):807-815.
9. Van Praet C, De Maeseneer D, Lumen N, Rottey S. Attacking the
androgen receptor pathway in prostate cancer. Belg J Med Oncol
2013;7(4):111-118.
10. Vermassen T, Rottey S. Highlights in genitourinary cancer ESMO. Belg J Med
Oncol. 2014;8(4):143-146.
11. Vermassen T, Kerst JM, Tombal B, Rottey S. The first Belgian multidisciplinary
meeting on urological cancers. Belg J Med Oncol 2014;8(5):224-227.
Curriculum Vitae Sylvie Rottey 17
12. El Ali Z, Van Brummelen D, Wolter P, Rottey S, Altintas S, Schallier D,
Debruyne P, Gennigens C, Van Aelst F, Sideris S, Gil T, Sirtaine N, D’Hondt
L, Luyten D, Focan C, Matus G, Rasschaert M, Pelgrims G. Management
and systemic treatment of clear cell mRCC: BSMO expert panel
recommendations. Belg J Med Oncol 2015;9(1):16-24.
13. Vermassen T, De Visschere P, Villeirs G, Schrijvers D, Rottey S. Second
Belgian multidisciplinary meeting on urological cancers held in Brussels –
March 28th, 2015. Belg J Med Oncol 2015;9(3):113-116.
14. Vermassen T, Rottey S. Highlights from ASCO 2015. Highlights in
genitourinary cancers. Belg J Med Oncol 2015;9(4):158-163.
15. Vermassen T, Rottey S. Highlights in genitourinary cancers. Belg J Med
Oncol 2015;9(6):244-249.
16. Rottey S, Van Bortel L, Christiaens T. Farmacotherapeutische actualiteit.
Tijdschrift Voor Geneeskunde 2015;71(17):1090-1094.
17. Delafontaine B, Van Lancker G, Van Bortel L, Rottey S. Virussen in de
behandeling van kanker: oncolytische virotherapie. Tijdschrift Voor
Geneeskunde. 2016;72(1):29-35.
18. Vermassen T, Rottey S. Highlights from ASCO 2016. Belg J Med Oncol.
2016;10(5):162-169.
19. Vermassen T, de Wit R, van Velthoven R, Albisinni S, Martinez Chanza N,
Aoun F, Seront E, Rottey S. 3rd Belgian Multidisciplinary Meeting on
Urological Cancers. Belg J Med Oncol. 2016;10(6):232-235.
20. Vermassen T, De Meulenaere A, Van de Walle M, Rottey S. Therapeutic
approaches in clear cell and non-clear cell renal cell carcinoma. Belg J
Med Oncol. 2016;10(7):256-262.
21. Vermassen T, Rottey S. ESMO 2016 – Highlights in genitourinary cancers.
Belg J Med Oncol. 2016;10(8):295-300.
22. Vermassen T, Rottey S, Van Bortel L, Christaens T. Framacotherapeutische
actualiteit. Tijdschrift Voor Geneeskunde. 2016;72(20):1154-1159.
23. Vermassen T, Rottey S. ASCO 2017 – Highlights in genitourinary cancers.
Belg J Med Oncol. 2017;11(4):155-60.
24. Vermassen T, Rottey S. ESMO 2017 – Highlights in genitourinary cancers.
Belg J Med Oncol. 2017;11(7):326-333.
25. De Keukeleire S, Kruse V, Rottey S. Merkel cell carcinoma and immune
checkpoint inhibition: where do we stand now? Belg J Med Oncol.
2018;12;30-32 (BJMO Immuno-oncology Special).
26. Vermassen T, Rottey S. ASCO 2018 – Highlights in genitourinary cancers.
Belg J Med Oncol. 2018;12(4):189-195.
Curriculum Vitae Sylvie Rottey 18
27. De Maeseneer D, Decaestecker K, Rottey S. Emerging concepts in
urothelial cancer. Belg J Med Oncol. 2018;12(5):212-217.
28. Standaert C, De Visschere PJ, Rottey S, Buelens S, Sundahl N, Villeirs GM.
MRI in prostate cancer diagnosis, surgical or radiation treatment, focal
therapy, active surveillance and follow-up. Belg J Med Oncol.
2018;12(7):313-318.
29. Vermassen T, Rottey S. ESMO 2018 – Highlights in genitourinary cancers.
Belg J Med Oncol. 2018;12(8):373-379.
BOOKS AND BOOK CHAPTERS
1. Kosmidis P, Schrijvers D, André F, Rottey S (Editors). Handbook on Medical
Oncology Emergencies, ESMO. 2005
2. Rottey S, Van Belle S. Handbook on Medical Oncology Emergencies,
ESMO, Book Chapter Hypercalcemia.
3. Kosmidis P, Schrijvers D, André F, Rottey S (Editors). Handbook of
Oncological Emergencies, ESMO, Chinese edition. 2006
4. Rottey S. 99mTc-HYNIC Annexin-V for monitoring response to
chemotherapy : Methodology and feasibility studies.
5. Oncologie, Praktische huisartsgeneeskunde. S. Rottey Auteur van
hoofdstuk 14: Prostaatkanker en de rol van de huisarts. 2017
6. Vermassen T, Callewaert N, Rottey S, Delanghe Jr. Prostate Protein N-
Glycosylation Profiling by Means of DNA Sequencer-Assisted Fluorophore-
Assisted Carbohydrate Electrophoresis. Methods Mol Biol. 2019;1972:235-
250.
PATIENT INFO
Chemotherapie - Infobrochure voor kankerpatiënten en hun familie. VLK 2005
Wetenschappelijke lectuur : Sylvie Rottey en Jan Van Gaver
ABSTRACTS AND POSTERS
1. Everaert E, Rottey S, Cocquyt V, De Vos F, Dierickx RA, Sleghers G, Van de
Wiele C. Iodine labelled Tamoxifen uptake in primary and metastatic
breast cancer. Abstract presentation on BSMO, januari 2001.
2. Grosjean M, Rottey S, Benard J. IGR-BR-11, a new breast cancer cell line
model derived from a germinal BRCA1 mutation carrier. Abstract
American Association for Cancer Research 2002.
3. Rottey S, Sabourin JC, Grosjean M, Rixe O, Van Belle S, Benard J. Cultures
of primary breast cancer. Feasability of spheroid model. Abstract ESEC
(ESMO Summer Educational Conference Edinburgh) June 2003 + Poster
Curriculum Vitae Sylvie Rottey 19
4. J. B. Vermorken, R. Mesia, M. E. Vega-Villegas, E. Remenar, R. Hitt, A.
Kawecki, S. Rottey, D. Zabolotnyy, J. Erfan, N. Amellal. Cetuximab in
combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the
first-line treatment of patients with recurrent and/or metastatic squamous
cell carcinoma of the head and neck (R&M SCCHN) (EXTREME). Journal
of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol
24, No. 18S (June 20 Supplement), 2006: 5537.
5. J. Vermorken, R. Mesia, V. Vega, E. Remenar, R. Hitt, A. Kawecki, S. Rottey,
N. Amellal, D. Cupissol, L. Licitra. Cetuximab extends survival of patients
with recurrent or metastatic SCCHN when added to first line platinum
based therapy - Results of a randomized phase III (Extreme) study. 2007
ASCO Annual Meeting, Oral Abstract Session, Head and Neck Cancer ,
Abstract No:6091.
6. T. E. Hutson, I. D. Davis, J. P. Machiels, P. L. de Souza, B. F. Hong, S. Rottey,
K. L. Baker, T. Crofts, L. Pandite, R. Figlin. Pazopanib (GW786034) is active
in metastatic renal cell carcinoma (RCC): Interim results of a phase II
randomized discontinuation trial (RDT). Journal of Clinical Oncology, 2007
ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20
Supplement), 2007: 5031.
7. I.Bambust , P.Pierre , E.Joossens , D.Schallier , F.Van Aelst , V.Renard ,
M.Clausse , R.Kalantari , R.Paulus , L.Duck , S.Luce , S.Rottey. A belgian
registry of interleukin-2 administration for treatment of metastatic renal
cell cancer. The Belgian Society for Fundamental and Clinical Physiology
and Pharmacology, november 2007, Oral presentation by S. Rottey
8. S. Rottey, H. Denys, H. Robays, L. Van Bortel, V. Cocquyt. Characteristics
and cardiac toxicity of thirty breast cancer patients treated with
trastuzumab in the adjuvant setting at the Ghent University Hospital
between June 2006 and July 2007: part of the trastuzumab convention.
De Nederlandse Vereniging voor Klinische Farmacologie & Biofarmacie,
april 2008, Utrecht : Oral presentation
9. S. Rottey, R. Hitt, A Kawecki, F. Peyrade, J.B. Vermorken
10. Cetuximab plus platinum-based chemotherapy vs platinum-based
chemotherapy alone in the first-line treatment of recurrent and/or
metastatic squamous cell carcinoma of the head and neck: a quality of
life analysis of the extreme trial. ICACT 2009 Poster
11. S Rottey, N Verbeke, L Vakaet, T Boterberg, W De Neve, K Bonte. Outcome
of T3 laryngeal cancer treated by primary surgery or primary
(chemo)radiation. ECCO 2009 Poster
Curriculum Vitae Sylvie Rottey 20
12. V. Grunwald, J-P. Machiels, K. Miller, PI. Karakiewicz, SY. Rah, S. Rottey, M.
Staehler, C. Eichelberg, J. Ahn, S-H. Lee. An International Expanded
Access Program (EAP) of Afinitor® (everolimus) in patients with metastatic
renal cell carcinoma (mRCC) who fail, or become intolerant of a prior
vascular endothelial growth factor receptor (VEGFr) therapy. IKCS 2009
Abstract International Kidney Cancer Symposium
13. E. Seront, S. Rottey, B. Sautois, L. A. D'Hondt, J. R. Canon, J. Vandenbulcke,
N. Whenham, J. Goeminne, D. Verhoeven, J. H. Machiels. A single arm,
multicenter, phase II trial of everolimus as monotherapy in the palliative
treatment of patients with locally advanced or metastatic transitional cell
carcinoma after failure of platinum-based chemotherapy. J Clin Oncol 28,
2010 (suppl; abstr e15087)
14. J. B. Vermorken, J. H. Machiels, S. Rottey, H. C. Thurm, K. Pelling, A.
Lahogue. Phase Ib study evaluating the combination of BIBW 2992 with
two different standard chemotherapy regimens, cisplatin/paclitaxel (PT)
and cisplatin/5-FU (PF), in patients with advanced solid tumors. J Clin
Oncol 28, 2010 (suppl; abstr e13521).
15. E. Seront, B. Sautois, S. Rottey, L. A. D'Hondt, J. Canon, J. Vandenbulcke,
N. Whenham, J. C. Goeminne, O. Feron, J. H. Machiels Phase II trial of
everolimus monotherapy in the palliative treatment of patients with
metastatic transitional cell carcinoma (TCC) after failure of platinum-
based therapy: Activity and biomarkers. J Clin Oncol 29: 2011 (suppl; abstr
4622).
16. P. R. Debruyne, T. Boterberg, H. Pottel, L. Goethals, N. Van den Noortgate,
F. Duprez, W. De Neve, S. Rottey, K. Geldhof, K. Van Eygen, K. Kargar-
Samani, V. Ghekiere, F. Cornelis, S. G. Mohile, L. Pottel. Can the Vulnerable
Elders Survey-13 and/or the G8 adequately identify elderly patients with
head and neck cancer in need of a comprehensive geriatric assessment?
J Clin Oncol 29: 2011 (suppl; abstr e19670)
17. J. Vermorken, S. Rottey, E. Ehrnrooth, K. Pelling, A. Lahogue, J. Machiels. A
Phase Ib Open-label Study to Assess Continuous Oral Treatment With
Afatinib (BIBW 2992) in Combination With Two Chemotherapy Regimens –
Cisplatin Plus Paclitaxel, and Cisplatin Plus 5-fluorouracil in Patients, With
Advanced Solid Tumours. ESMO 2011, poster 1204.
18. V. Kruse, A. De Both, S. Van Belle, S. Rottey. Retrospective analysis of
metastatic renal cell cancer patients treated with sunitinib : does dose
matter? Abstract and oral presentation BSMO 2012
Curriculum Vitae Sylvie Rottey 21
19. Bracarda, S., Rottey, S., Bahl, A., Eichelberg, C., Mellado, B., Mangel, L.,
Mardiak, J., Bouzaklas, I., Panneerselvam, A., Grünwald, V. International,
expanded-access programme of everolimus in patients with metastatic
renal cell carcinoma who progressed after prior vascular endothelial
growth factor receptor-tyrosine kinase inhibitor therapy: Sub-analysis of
European patients. Abstract EAU 2012
20. James Lloyd Wade, Shaker R. Dakhil, Ari David Baron, Sylvie Rottey,
Frederick E. Millard, Gedske Daugaard, Jean-Pascal H. Machiels, William
A. Conkright, Sunil Sharma, Patricia M.M.B. Soetekouw, Jeffrey Yachnin,
Lisa Sengeløv, Peter van Veldhuizen, Sanjiv S Agarwala, TX Quyen Nguyen,
Mustapha Chadjaa, Pierre Maison-Blanche. A QTc study of cabazitaxel in
patients with advanced solid tumors. J Clin Oncol 30, 2012 (suppl 5; abstr
257)
21. V. Kruse, A. De Both, S. Van Belle, S. Rottey. Retrospective analysis of
metastatic renal cell cancer patients treated with sunitinib : does dose
matter? Abstract oral presentation BSMO annual meeting 11/2/2012.
22. V. Kruse MD, A. De Both MD, N. Beck PharmD , L. Van Bortel MD PhD, S.
Van Belle MD PhD, S. Rottey MD PhD. Retrospective analysis of metastatic
renal cell cancer patients treated with sunitinib and the role of possible
interactions. Poster presentation NVKFB, 30/04/2012.
23. Pascal Wolter, Tine Hendrickx, Vincent Renard, Jeroen Mebis, Philip R.
Debruyne, Wim Wynendaele, Denis C. C. Schallier, Joanna Vermeij, Aldrik
Nielander, Jean-Pascal H. Machiels, Sylvie Rottey, Stephanie Delande,
Jean-Charles Goeminne, Patrick Schoffski, Sandra De Coster, Valerie
Lacour, Veerle Foulon Adherence to oral anticancer drugs (OAD) in
patients (pts) with metastatic renal cancer (mRCC): First results of the
prospective observational multicenter IPSOC study (Investigating Patient
Satisfaction with Oral Anti-cancer Treatment). 2012 ASCO Annual
Meeting; J Clin Oncol 30, 2012 (suppl; abstr 4622)
24. Jan Stoehlmacher-Williams, Cristian Villanueva, Paolo Foa, Sylvie Rottey,
Eric Winquist, Lisa F. Licitra, Irina Davidenko, Krzysztof A. Skladowski, Makoto
Tahara, Sandrine J. Faivre, Kelly S. Oliner, Zhiying Pan, Bruce A. Bach, Jan
Baptist Vermorken Safety and efficacy of panitumumab (pmab) in HPV-
positive (+) and HPV-negative (-) recurrent/metastatic squamous cell
carcinoma of the head and neck (R/M SCCHN): Analysis of the global
phase III SPECTRUM trial. 2012 ASCO Annual Meeting; J Clin Oncol 30, 2012
(suppl; abstr 5504^)
25. James Lloyd Wade, Shaker R. Dakhil, Ari David Baron, Sylvie Rottey,
Frederick E. Millard, Gedske Daugaard, Jean-Pascal H. Machiels, William
A. Conkright, Sunil Sharma, Patricia M.M.B. Soetekouw, Jeffrey Yachnin,
Curriculum Vitae Sylvie Rottey 22
Lisa Sengeløv, Peter van Veldhuizen, Sanjiv S. Agarwala, TX Quyen
Nguyen, Mustapha Chadjaa, Pierre Maison-Blanche. A QTc study of
cabazitaxel in patients with advanced solid tumors. 2012 ASCO Annual
Meeting; J Clin Oncol 30, 2012 (suppl; abstr e15115)
26. Van Praet Charles, Lumen Nicolaas, Decaestecker Karel, Fonteyne
Valérie, De Meerleer Gert, De Maeseneer Daan, Van Belle Simon, Rottey
Sylvie. Abiraterone acetate for castration-resistant prostate cancer
following docetaxel: our initial experience. Global Congress On Prostate
Cancer, June 2012, Brussels
27. Awada, J.P. Delord, N. Houédé, C. Lebbe, T. Lesimple, J.H.M. Schellens, S.
Rottey, R. Kefford, N. Rejeb, E. Raymond. Safety and Recommended
Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib
(MSC1936369B/AS703026): Results of a Phase I Trial : poster presentation at
the 24th EORTC-NCI-AACR Symposium on ‘Molecular Targets and Cancer
Therapeutics’, 6-9 November 2012 Dublin, Ireland
28. N. Houédé, J.P. Delord, A. Awada, C. Lebbe, T. Lesimple, J.H.M. Schellens,
S. Rottey, R. Kefford, O. von Richter, E. Raymond. Pharmacokinetics and
Pharmacodynamics of a Selective Oral MEK1/2 Inhibitor, Pimasertib
(MSC1936369B/AS703026), in Patients with Advanced Solid Tumors. poster
presentation at the 24th EORTC-NCI-AACR Symposium on ‘Molecular
Targets and Cancer Therapeutics’, 6-9 November 2012 Dublin, Ireland
29. J.P. Delord, N. Houédé, A. Awada, C. Lebbe, T. Lesimple, J.H.M. Schellens,
S. Rottey, R. Kefford, N. Rejeb, E. Raymond. Pimasertib
(MSC1936369B/AS703026), a Selective Oral MEK1/2 Inhibitor, Shows
Clinical Activity in Melanoma. poster presentation at the 24th EORTC-NCI-
AACR Symposium on ‘Molecular Targets and Cancer Therapeutics’, 6-9
November 2012 Dublin, Ireland
30. De Both A. , V. Kruse, E. De Coene, N. Clottens, A. Somers, S. van Belle, L.
van Bortel, S. Rottey. COMPLIANCE WITH SUNITINIB TREATMENT IN PATIENTS
WITH RENAL CELL CANCER. ESMO congress 2012, Vienna.
31. P.R. Debruyne, M. Lycke, T. Boterberg, H. Pottel, L. Goethals, N. van den
Noortgate, F. Duprez, S. Rottey, K. Kargar-Samani, L. Pottel. SERIAL
COMPREHENSIVE GERIATRIC EVALUATION IN ELDERLY HEAD AND NECK
CANCER PATIENTS UNDERGOING RADIOTHERAPY. Poster presentation at
ESMO congress 2012 Vienna.
32. Van Praet Charles, Libbrecht Louis, Rottey Sylvie, Praet Marleen, Van Belle
Simon, Lumen Nicolaas. Androgen receptor gene amplification in primary
prostate cancer patients. Poster op European Section on Urological
Research (ESUR) 10/2012
Curriculum Vitae Sylvie Rottey 23
33. Prostate specific antigen glycosylation profile may serve as a diagnostic
biomarker for prostate cancer. Vermassen, T., Lumen, N., Van Praet, C.,
Vanderschaeghe, D., Callewaert, N., Hoebeke, P., Van Belle, S.,
Delanghe, J., Rottey, S. Abstract. Belg J Med Oncol 2013;7(2):63-67.
Accepted for oral presentation at 15th annual meeting Belgian Society for
Medical Oncology (BSMO), Brussels, 02/03/2013
34. Prostate specific antigen glycosylation profile may serve as a diagnostic
biomarker for prostate cancer. Vermassen, T., Van Praet, C., Lumen, N.,
Vanderschaeghe, D., Callewaert, N., Hoebeke, P., Van Belle, S.,
Delanghe, J., Rottey, S. Abstract 22. PROSCA Abstractbook 2013; p20.
Accepted for poster presentation at 2nd Edition of the Global Congress
on Prostate Cancer (PROSCA), Marseille, 12-14/06/2013.
35. Prostate proteins glycosylation profile and its potential as a diagnostic
biomarker for prostate cancer. Vermassen, T., Lumen, N., Van Praet, C.,
Vanderschaeghe, D., Callewaert, N., Hoebeke, P., Van Belle, S., Rottey, S.,
Delanghe, J. Abstract A-14. Clin Chem 2013; 59(10)S:A5. Accepted for oral
presentation at Annual Meeting American Association for Clinical
Chemistry (AACC), Houston, 31/07/2013
36. Prostate proteins glycosylation profile as a potential diagnostic biomarker
for prostate cancer. Vermassen, T., Van Praet, C., Vanderschaeghe, D.,
Lumen, N., Callewaert, N., Hoebeke, P., Van Belle, S., Rottey, S. , Delanghe,
J. Abstract 23. Oncopoint II Abstractbook 2014; p32. Accepted for oral
bullet presentation at OncoPoint II Ghent University, Ghent, 06/02/2014
37. Platinum-based chemotherapy (CT) plus cetuximab in recurrent or
metastatic squamous cell carcinoma of the head and neck cancer (R/M-
SCCHN): 5-year follow-up data for the extreme trial. Jan Baptist
Vermorken, Eva Remenar, Ricardo Hitt, Andrzej Kawecki, Sylvie Rottey,
Luise Knierim, Jeltje Schulten, Ricard Mesia J Clin Oncol 32:5s, 2014 (suppl;
abstr 6021)
38. A phase I, first-in-human study of ARGX-110, a monoclonal antibody
targeting CD70, a receptor involved in immune escape and tumor growth
in patients with solid and hematologic malignancies) Ahmad Awada,
Christian D. Rolfo, Sylvie Rottey, Laure Ysebrant de Lendonck, Wilfried A.
Schroyens, Fritz Offner, Karen Silence, Torsten Dreier, Mahan Moshir, Hans
de Haard, Marc Peeters, Dominique Bron, Alain Thibault, Philippe G.
Aftimos. J Clin Oncol 32:5s, 2014 (suppl; abstr 3023)
39. A first-in-class, first-in-human phase I study of enadenotucirev, an oncolytic
Ad11/Ad3 chimeric group B adenovirus, administered intravenously in
patients with metastatic epithelial tumors. Emiliano Calvo, Marta Gil-
Martin, Jean-Pascal H. Machiels, Sylvie Rottey, Antonio Cubillo, Ramon
Curriculum Vitae Sylvie Rottey 24
Salazar, Feby Ingriani Mardjuadi, Karen Paula Geboes, Christopher Ellis,
John William Beadle, Christine Blanc. J Clin Oncol 32:5s, 2014 (suppl; abstr
3103)
40. Prostate proteins glycosylation profile as a potential diagnostic biomarker
for prostate cancer. Vermassen, T., Van Praet, C., Vanderschaeghe, D.,
Lumen, N., Callewaert, N., Hoebeke, P., Van Belle, S., Rottey, S. , Delanghe,
J. Wetenschapsdag Ghent University, Ghent, 13/03/2014. Accepted for
oral bullet presentation at Wetenschapsdag Ghent University, Ghent,
13/03/2014
41. Possible use of urinary prostate proteins glycosylation profile as a
diagnostic biomarker for prostate cancer.Vermassen, T., Lumen, N., Van
Praet, C., Vanderschaeghe, D., Callewaert, N., Hoebeke, P., Van Belle, S.,
Delanghe, J., Rottey, S. Abstract 236P. Ann Oncol 2014; 25(4)S:iv79.
Accepted for poster presentation at 39th annual congress European
Society for Medical Oncology (ESMO), Madrid, 26-30/09/2014.
42. Prostate cancer diagnosis through prostate proteins glycosylation.
Vermassen, T., Van Praet, C., Lumen, N., Decaestecker, K.,
Vanderschaeghe, D., Callewaert, N., Villeirs, G., Hoebeke, P., Van Belle, S.,
Delanghe, J., Rottey, S. Abstract 35. Oncopoint III Abstractbook 2015.
Accepted for oral bullet presentation at OncoPoint III Ghent University,
Ghent, 11/02/2015
43. Evaluation of abiraterone acetate post-docetaxel in the Belgian
compassionate use program. Sylvie Rottey, Charles Van Praet, Fransien
Van Hende, Gino Pelgrims, Wim Demey, Filip Van Aelst, Wim Wynendaele,
Thierry Gil, Peter Schatteman, Bertrand Filleul, Denis C. C. Schallier, Jean-
Pascal H. Machiels, Dirk L. Schrijvers, Els Grieta Everaert, Lionel A. D'Hondt,
Patrick Werbrouck, Joanna Vermeij, Jeroen Mebis, Marylene Clausse,
Nicolaas Lumen. J Clin Oncol 33, 2015 (suppl; abstr e16057)
44. Randomized phase II study of cabazitaxel versus methotrexate in patients
with recurrent or metastatic squamous cell carcinoma of the head and
neck (SCCHN) previously treated with platinum-based therapy. Sylvie
Rottey, Aline Van Maanen, Jean-Marie Vandenbulcke, Bertrand Filleul,
Emmanuel Seront, Stefanie Henry, Lionel A. D'Hondt, Christophe Lonchay,
Stephane Holbrechts, Petra Boegner, Dany J. Brohee, Didier Dequanter,
Ingrid Louviaux, Brieuc Sautois, Nicolas Whenham, Guy J. Berchem, Brigitte
Vanderschueren, Christel Fontaine, Sandra Schmitz, Jean-Pascal H.
Machiels. J Clin Oncol 33, 2015 (suppl; abstr 6051)
45. Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian
target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally
advanced or metastatic transitional cell carcinoma (TCC). Emmanuel
Seront, Sylvie Rottey, Bertrand Filleul, Phillipe Glorieux, Jean Charles.
Curriculum Vitae Sylvie Rottey 25
Goeminne, Jean-Marie Vandenbulcke, Brieuc Sautois, Petra Boegner,
Vincent Verschaeve, Aline Gillain, Aline Van Maanen, Jean-Pascal H.
Machiels. J Clin Oncol 33, 2015 (suppl; abstr e15535).
46. Effect of itraconazole and rifampin on the pharmacokinetics of olaparib
tablet formulation in patients with advanced solid tumours: Phase I open-
label studies. Elizabeth R. Plummer, Henk M.W. Verheul, Sylvie Rottey, Karin
Leunen, Guy Heinrich Maria Jerusalem, Christian D. Rolfo, Dorte L. Nielsen,
L Rhoda Molife, Rebecca Kristeleit, Judith de Vos-Geelen, Morten Mau-
Sørensen, Patricia M.M.B. Soetekouw, Carla van Herpen, Helen Swaisland,
Anitra Fielding, Karen So, Wendy Bannister, Luc Dirix. J Clin Oncol 33, 2015
(suppl; abstr 2565).
47. A. De Meulenaere, T. Vermassen, S. Aspeslagh, P. Deron, F. Duprez, K.
Silence, J. Jacobs, K. Zwaenepoel, P. Pauwels, S. Rottey, L. Ferdinande.
Immunohistochemical analysis of CD70 expression in 95 cases of
squamous cell carcinoma of the head and neck: Correlation with
clinicopathological variables and identification of a novel therapeutic
target. ECCO 2015, abstract 2880.
48. Vermassen, T., Poelaert, F., Lumen, N., Geboes, K., Delanghe, J., Rottey, S.
Assessment of renal toxicity in oncology patients treated with targeted
agents. Abstract. Belg J Med Oncol 2016. Poster presented at the Belgian
Society for Medical Oncology annual meeting, Brussels 27/02/2016.
49. De Meulenaere, A., Vermassen, T., Deron, F., Ferdinande, L., Rottey, S. A
pilot, phase Ib feasibility study of ARGX-110 in patients with
nasopharyngeal carcinoma (NPC). Abstract. Belg J Med Oncol 2016.
Poster presented at the Belgian Society for Medical Oncology annual
meeting, Brussels 27/02/2016.
50. Vermassen, T., Lumen, N., Delanghe, J., Rottey, S. Impact of haptoglobine
polymorphism on survival of renal cell carcinoma patients. Abstract 906P.
Ann Oncol 2017;28(S5):v295-v329. Poster presented at the European
Society for Medical Oncology annual meeting, Madrid 10/09/2017.
51. De Meulenaere, A., Vermassen, T., Rottey, S., Ferdinande, L. Phenotyping
of the immune infiltrate in oropharyngeal squamous cell carcinoma: focus
on materials and methods. Abstract 1063P. Ann Oncol 2017;28(S5):v372-
v394. Poster presented at the European Society for Medical Oncology
annual meeting, Madrid 10/09/2017.
52. Vermassen, T., Lumen, N., Delanghe, J., Rottey, S. Early biomarkers for TKI-
induced renal damage in mRCC patients. Abstract presented at the 6th
Belgian Multidisciplinary Meeting on Urological Cancers, Brussels
30/03/2019.
Curriculum Vitae Sylvie Rottey 26
EXTRA-CURRICULAR ACTIVITIES AND MEMBERSHIPS
ESMO fellowship award 2001-2002 ESMO
Fellowship October 2001 – tember 2002
o Gustave Roussy institute (Service de Génétique, J. Benard, Villejuif,
Paris - research)
o Descartes University (Paris V) (Department Medical Oncology, D.
Khayat, Hôpital pitié Salpétrière, Paris – clinical trials)
Member of steering committee of Young Medical Oncologists of ESMO
(2000-2004)
Full Member of BSMO (Belgian Society of Medical Oncology)
Full member of ESMO (European Society of Medical Oncology)
Full member of ASCO (American Society of Medical Oncology)
Member of the Flemish Head and Neck Oncology Cooperative Group
Full Member of NVKFB (Nederlandse Vereniging voor Klinische
Farmacologie en Biofarmacie)
Full Member of BAPU (Belgian Association of Phase I Units)
Board Member of BAPU (since 25/06/2010)
Member of the multidisciplinary working group of uro-oncology at the
Ghent University Hospital
Member of the multidisciplinary working group of Head and Neck cancer
at the Ghent University Hospital
Member of committee of implantable ports of the Ghent University
Hospital , now IV team
Coordinating physician of the phase I oncology working group of the
Ghent University Hospital (from 2009)
Member of the FTC (Faramcotherapiecel) of the Ghent University Hospital
(start 2007)
Member of the MFC (Medisch Farmaceutisch Comite) of the Ghent
University Hospital (start 2009) – specialst in oncology
Member of the EORTC Head and Neck cancer working group
Member of the EORTC GU cancer working group
Member of the International Editorial Board of the journal ENHANCER 2006 -
2008
Member of the advisory board magazine VLK : Leven
Member of the editorial board ONCO from 2008
Curriculum Vitae Sylvie Rottey 27
Member of the steering group organising postgraduate of internal
medicine of the University of Ghent
Reviewer of the journal
o Nephrology Dialysis Transplantation
o Acta Clinica Belgica
o Belgian Journal of Medical Oncology
o Oral Oncology
o European Journal of Nuclear Medicine and Molecular Imaging
o Advances in Urology
o Journal of Cancer Research and Clinical Oncology
o Onkologie
o Journal for Cancer research and Therapeutics
Coordinator LOK O-Vlaanderen (since 2008)
Member of Expert Meeting of the College of Oncology for the KCE Project
Testicular Cancer
Member ‘permanente werkgroep farmaca in de oncologie’ RIZIV
Member oncology care program / steering committee Ghent University
Hospital
Member of PONt (Psychosociaal Oncologisch team) from the oncology
care program Ghent University Hospital (start 10/2011).
Guest Editor ‘CME Series of Oncology for the Internist’ for Acta Clinica
Belgica, 2010 - 2011
Expert oncology for the bcfi – Belgisch Centrum voor Farmaceutische
Informatie
Member of numerous advisory boards on a national and international
level
Advisory Board Member for Framingham on Head and Neck cancer
(since 11/2011)
Co-editor of 7th edition (2011) of ‘Verpleegkundig oncologisch
compendium’
Experience in clinical trials phase I-III
Member of the BSMO prostate task force – president
Member of the BSMO renal cell cancer task force
Membre consultatif de la Fondation Registre du Cancer
National representative ESMO for Belgium (2013-2016)
Board member of the BSMO (start 2013)
Curriculum Vitae Sylvie Rottey 28
GCP certificate renewal October 2013 – update on a yearly basis
Verantwoordelijke arts voorschrijverswerkgroep MFC UZGent Anti-emetica
en bifosfonaten (From 2013).
Rijksinstituut voor ziekte- en invaliditeitsverzekering. – Paritair comité voor
medische oncologie : werkend lid sinds juli 2013
2013 : IWT funding : ARGX-110 Adaptive Phase I Clinical Trial & Companion
Diagnostic Kit Development
2013 : Vlerick Business School, management voor de
ziekenhuisprofessional : Module people (2 days)
Module finance (2 days)
Chairman Expert Meeting of the College of Oncology for the KCE Project
renal cancer 2014-2015
Member of the KCE guideline development group : the Belgian clinical
practice guideline for the oncogenetic testing for 'BHD Syndrome, FAMMM
Syndrome, Neurofibromatosis 1&2' (2014)
Expert in the KCE project “Good Clinical Practice Guideline for Bladder
Cancer” Belgium 2014-2015
Board Member of the Flemish working group on Head and Neck cancers
(VWHHT) – since 6/2015
Vice president of MFC of the hospital (10/2015)
Vice president of BAPU (end of 2015)
Member of the editorial board of BJMO Belgian Journal of Medical
Oncology (1/2016)
PI of numerous phase I trials (Healthy Volunteers and Oncology patients)
in the Drug Research Unit Ghent
Member of CRIG (Cancer Research Institute Ghent) – CRIG group leader
(from 2016)
President of BMUC (Belgian Multidisciplinary Meeting on Urological
Cancers) since 2015
2017 : following course MDP – Management Development Program –
Ghent University Hospital – Ghent
Erkend opleider Klinische Farmacologie voor de NVKFB (de
NederlandseVereniging van Klinische Farmacologie en Biofarmacie)
since 2016
President of the scientific committee of the Pfizer Oncology Award since
2016
Curriculum Vitae Sylvie Rottey 29
Member of the steering group on integrated care in CRPC setting
Jury member for the Galenus Prize for Pharmacology from 2020 onward
Expert oncologie Folia Pharmacotherapeutica
Member of the EHNS-European Head & Neck Society
President BAPU (March 2019)
Vice President BSMO (Feb 2019)
President FTC and MFC of UZGent
Replacing member CTG RIZIV
Member of the working group RIZIV : permanente werkgroep ONCO
Member of EUFEMED (European Federation for Exploratory Medicines
Development)
LANGUAGES
Dutch : fluent
English : fluent
French : fluent
German : basic knowledge
SOFTWARE
Practical knowledge of MS Office
LEISURE
Diploma oral presentation
Classical music (diploma violin)
Travelling
My Family
----------------------------------------------------------------------------------------------------------------------------------------